⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 28, 2024Expert Review of VaccinesOpen Access

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands

Cody Palmer F Christiaan K Dolk Ugne Sabale Wei Wang Kunal Saxena

View Full Paper

Ask AI

Bookmark

Share

Abstract

Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Palmer et al. (2024) studied this question.

synapsesocial.com/papers/68e77206b6db6435876e6db0 https://doi.org/10.1080/14760584.2024.2322543

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Vaccine Effectiveness Of Bivalent HPV Vaccination Against Genital HPV Of A Catch-Up Campaign And 12 Years Routine Vaccination For Girls-Only: A Biennial Repeated Cross-Sectional Study2024 · 3 citations
2Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination2024 · 15 citations
3Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan2025 · 2 citations
4Will cervical screening remain cost‐effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countriesCost-Effectiveness Analysis · 2016 · 77 citations
5Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverageOriginal Research · 2026

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence2017
Cost-effectiveness of female-only and gender-neutral HPV vaccination strategies in Japan2026
Health economic impact and cost threshold for switching from bivalent to nonavalent HPV vaccination for preadolescent girls in KwaZulu Natal, South Africa: A mathematical modeling analysis accounting for the HIV epidemic2026
Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trialsExpert Review of Vaccines · 2026
The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysisExpert Review of Vaccines · 2026

More from Expert Review of Vaccines

More from Merck & Co., Inc., Rahway, NJ, USA (United States)

More from Decision Sciences (United States)

More from MSD (Lithuania)